Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pirepemat (IRL752) fumarate can be used in Parkinson's disease study. Pirepemat is a cortical-preferring catecholamine transmission- and cognition-promoting agent [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 916.00 | |
50 mg | 6-8 weeks | $ 1,190.00 | |
100 mg | 6-8 weeks | $ 1,860.00 |
Description | Pirepemat (IRL752) fumarate can be used in Parkinson's disease study. Pirepemat is a cortical-preferring catecholamine transmission- and cognition-promoting agent [1] [2]. |
In vitro | IRL752 fumarate exhibits its strongest in vitro affinities primarily for serotonin (5-HT) and norepinephrine (NA)-related targets [2]. |
In vivo | IRL752 fumarate, administered subcutaneously at dosages ranging from 3.7 to 100 μmol/kg, does not significantly influence acute hyperdopaminergic or hypoglutamatergic motor responses. However, it effectively reverses impairments associated with reduced monoaminergic function. In normal rats tested 30 minutes after administration, IRL752 induced dose-dependent and region-specific changes in brain monoamine transmission indices and gene expression, showcasing its potential in modulating neurotransmitter system dysfunctions. |
Molecular Weight | 329.3 |
Formula | C15H17F2NO5 |
CAS No. | 2251806-70-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pirepemat fumarate 2251806-70-7 inhibitor inhibit